Stock 4563 ANGES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company AnGes, Inc.

Equities

4563

JP3127700007

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-31 am EDT 		5-day change 1st Jan Change
46 JPY -.--% Intraday chart for AnGes, Inc. -2.13% -36.11%
Jan. 19 Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease MT
Jan. 18 Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan CI

Business Summary

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
12 100.0 % 23 100.0 % +100.12%

Sales per region

JPY in Million2022Weight2023Weight Delta
Japan
100.0 %
12 100.0 % 23 100.0 % +100.12%

Managers

Managers TitleAgeSince
Tetsuji Yoneo DFI
 Director of Finance/CFO 54 12-09-30
Ei Yamada PSD
 President 74 01-04-30
Kazuo Suzuki CTO
 Chief Tech/Sci/R&D Officer 67 19-01-31
Hajime Watanabe CTO
 Chief Tech/Sci/R&D Officer - -
Jun Sakurai IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Ei Yamada PSD
 President 74 01-04-30
Makoto Hara BRD
 Director/Board Member 73 18-03-28
Junichi Komamura BRD
 Director/Board Member 74 12-02-29
Tetsuji Yoneo DFI
 Director of Finance/CFO 54 12-09-30
Norikazu Eiki BRD
 Director/Board Member 76 14-04-30
Kazuo Suzuki CTO
 Chief Tech/Sci/R&D Officer 67 19-01-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 228,968,550 222,159,958 ( 97.03 %) 92 ( 0.000040 %) 97.03 %

Shareholders

NameEquities%Valuation
Yuichiro Hayashi
0.6248 %
1,360,000 0.6248 % 423 477 ¥
SHIONOGI & CO., LTD.
0.5452 %
1,186,800 0.5452 % 369 546 ¥
Hiroshi Kawai
0.5007 %
1,089,800 0.5007 % 339 342 ¥
Ryuichi Morishita
0.3177 %
691,600 0.3177 % 215 350 ¥
Kyoko Fujita
0.3007 %
654,500 0.3007 % 203 798 ¥
Toshimi Otsuki
0.2986 %
650,000 0.2986 % 202 397 ¥
Chikanori Mizuno
0.2855 %
621,500 0.2855 % 193 523 ¥
Tatsuo Kagawa
0.2547 %
554,300 0.2547 % 172 598 ¥
SPARX Asset Management Co., Ltd.
0.0185 %
40,300 0.0185 % 12 549 ¥
Dimensional Fund Advisors Ltd.
0.009284 %
20,208 0.009284 % 6 292 ¥

Holdings

NameEquities%Valuation
FUNPEP COMPANY LIMITED
0.77%
 200,000 0.77% 188,098 $
FRESH TRACKS THERAPEUTICS, INC.
0.11%
 6,535 0.11% 6,019 $

Company contact information

AnGes, Inc.

Saito Bio-Incubator, 1/F 7-7-15 Saito-Asagi

567-0085, Osaka

+

http://www.anges.co.jp
address AnGes, Inc.(4563)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANGES, INC. Stock AnGes, Inc.
-36.11% 66.99M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
INSMED INCORPORATED Stock Insmed Incorporated
+77.64% 8.87B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4563 Stock
  4. Company AnGes, Inc.